Pulmonary Drug Delivery Systems: Technologies and Global Markets

Dec 2022| HLC094D| BCC Publishing

Report Highlights

The global pulmonary drug delivery systems market should reach $76.9 billion by 2027 from $57.4 billion in 2022 at a compound annual growth rate (CAGR) of 6.0% for the forecast period of 2022 to 2027.

Report Includes

  • 44 tables
  • A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
  • Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
  • Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
  • In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
  • Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
  • Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
  • Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
  • Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.

Report Scope

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.

In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.

The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.

Frequently Asked Questions (FAQs)

• The global market for pulmonary drug delivery systems was valued at $54.1 billion in 2021 and is projected to reach $76.9 billion by the end of 2027 at a CAGR of 6.0% for the forecast period of 2022-2027.
• The key factors driving the growth of the pulmonary drug delivery market include the rising prevalence of asthma and COPD cases and technological advancements.
• The pulmonary drug delivery systems market is segmented based on product, Type of Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and Nebulizers.
• The Asthma segment will dominate the market by the end of 2027.
• North America holds the highest share of the market.
• Key companies in the market include 3M, AstraZeneca, Cipla and GlaxoSmithKline.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022 to 2027
Base year market size $54.1 billion
Market size forecast $76.9 billion
Growth rate CAGR of 6.0% for the forecast period of 2022-2027
Units considered $ Millions
Segments covered Type, Disease Area, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (ROW)
Countries covered U.S., Canada, Mexico, U.K., Germany, France, Russia, Italy, Rest of Europe, China, India, Japan, South Korea, Rest of Asia-Pacific, South America, and Middle East and Africa (MEA)
Key Market Drivers
  • Improved Patient Compliance and Ease of Use
  • Cost Pressures on Countries
  • Rising Incidence of Asthma
  • Reducing the Burden of Asthma
  • Competition from Generics on the Rise
  • Introduction of Smart Nebulizers
Companies studied
  • 3M
  • ABBOTT
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CIPLA INC.
  • DR. REDDY'S LABORATORIES LTD.
  • GSK PLC.
  • KONINKLIJKE PHILIPS N.V.
  • LUPIN
  • MYLAN N.V.
  • MERCK KGAA
  • NOVARTIS AG
  • OMRON CORP.
  • PFIZER INC.
  • PULMATRIX INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Pulmonary Drug Delivery Systems: Technologies and Global Markets148Free
Chapter- 1: Introduction8Free
Chapter- 2: Summary and Highlights2Free
Chapter- 3: Market Dynamics and Technology Background12Free
Chapter- 4: Market Breakdown by Pulmonary Drug Delivery Systems9Free
Chapter- 5: COVID-19 Impact4Free
Chapter- 6: Pulmonary Drug Delivery Systems in Use5Free
Chapter- 7: Market Breakdown by Disease Area9Free
Chapter- 8: Market Breakdown by Region14Free
Chapter- 9: Patent Analysis56Free
Chapter- 10: Company Profiles27Free
Chapter- 11: Appendix: Abbreviations2Free
Published - May-2018| Analyst - BCC Publishing| Code - HLC094C

Report Highlights

The global pulmonary drug delivery systems market totaled $38.1 billion in 2017 and is estimated to reach $47.0 billion by 2022, growing at a compound annual growth rate (CAGR) of 4.3% for the period of 2017-2022.

Report Includes

  • 74 tables
  • A detailed overview and analysis of the global markets for pulmonary drug delivery systems
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
  • A look at the regulatory environment, which has been a driving force in the healthcare industry
  • Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
  • Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd
Published - May-2014| Analyst - Usha Nagavarapu| Code - HLC094B

Report Highlights

The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.

 Report Includes

  • A detailed overview and thorough analysis of the present and future global markets for pulmonary drug delivery technologies
  • Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Identification of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems
  • Information on technological developments, product innovations, and recent strategic industry activities of major players across different product categories
  • Examination of devices currently being used for drug delivery to the lungs, new developments, spending trends, and revenue prospects for these technologies
  • Comprehensive profiles of leading companies in the industry.

Published - Jan-2012| Analyst - Usha Nagavarapu| Code - HLC094A

Report Highlights

The global pulmonary drug delivery technologies market which was $19.6 billion in 2010 is expected to be around $22.5 billion by 2011. This global market is further projected to reach nearly $44 billion by 2016 at a compound annual growth rate (CAGR) of 14.3%.

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS